Skip to main content
Erschienen in: The European Journal of Health Economics 2/2006

01.07.2006 | Original Paper

Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis

verfasst von: Gisela Kobelt, Jenny Berg, Peter Lindgren, Bengt Jönsson

Erschienen in: The European Journal of Health Economics | Sonderheft 2/2006

Einloggen, um Zugang zu erhalten

Abstract

The objective of this observational study in nine European countries was to establish the current cost of MS at different levels of disease severity. The study used a prevalence-based bottom-up to estimate costs from a societal perspective. Patients were recruited via patient organizations and neurology centres and asked by mail to complete a detailed questionnaire concerning their resource consumption, work capacity, quality of life and current disease status. Resources included all health-care and social services, personal expenditures, informal care and temporary or definitive work absence. Quality of life was collected as utility and disease information collected related to functional capacity, relapses and fatigue. The data were analyzed separately for each country, using local unit costs but a fully standardized methodology. A total of 13 186 patients at all levels of disease severity participated in the survey, with an average response rate of around 40% (range 20–75%).
This paper describes the methodology used for the study, while results are presented in the individual country reports.
Literatur
1.
Zurück zum Zitat Holmes J, Madgwick T, Bates D (1995) The cost of multiple sclerosis. Br J Med Econ 8: 181–193 Holmes J, Madgwick T, Bates D (1995) The cost of multiple sclerosis. Br J Med Econ 8: 181–193
2.
Zurück zum Zitat Henriksson F, Jönsson B (1998) The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics 13: 597–606 CrossRef Henriksson F, Jönsson B (1998) The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics 13: 597–606 CrossRef
3.
Zurück zum Zitat Carton H, Loos R, Pacolet J, Versieck K, Vlietinck R (1998) Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J Neurol Neurosurg Psychiatry 64: 444–450 Carton H, Loos R, Pacolet J, Versieck K, Vlietinck R (1998) Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J Neurol Neurosurg Psychiatry 64: 444–450
4.
Zurück zum Zitat Kobelt G, Lindgren P, Parkin D et al. (2000) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the United Kingdom. SSE/EFI Working Paper Series in Economics and Finance No. 398. Stockholm School of Economics, Stockholm, Sweden Kobelt G, Lindgren P, Parkin D et al. (2000) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the United Kingdom. SSE/EFI Working Paper Series in Economics and Finance No. 398. Stockholm School of Economics, Stockholm, Sweden
5.
Zurück zum Zitat Henriksson F, Fredrikson S, Masterman T, Jönsson B (2001) Costs, quality of life and disease severity in multiple sclerosis. A cross-sectional study in Sweden. Eur J Neurol 8: 27–35CrossRefPubMed Henriksson F, Fredrikson S, Masterman T, Jönsson B (2001) Costs, quality of life and disease severity in multiple sclerosis. A cross-sectional study in Sweden. Eur J Neurol 8: 27–35CrossRefPubMed
6.
Zurück zum Zitat Kobelt G, Lindgren P, Smala A, Jönsson B, Group GCoMS (2001) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in Germany. Eur J Health Econ 2: 60–68 CrossRef Kobelt G, Lindgren P, Smala A, Jönsson B, Group GCoMS (2001) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in Germany. Eur J Health Econ 2: 60–68 CrossRef
7.
Zurück zum Zitat Amato MP, Battaglia MA, Caputo D et al. (2002) The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 249: 152–163CrossRefPubMed Amato MP, Battaglia MA, Caputo D et al. (2002) The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 249: 152–163CrossRefPubMed
8.
Zurück zum Zitat Russo P, Capone A, Paolillo A, Al E (2004) Cost analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. Clin Drug Invest 24: 409–420 CrossRef Russo P, Capone A, Paolillo A, Al E (2004) Cost analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. Clin Drug Invest 24: 409–420 CrossRef
9.
Zurück zum Zitat Kazas E, Grisouard R, Zanni J et al. (2003) Multiple sclerosis treatment with interferon beta: prevalence and cost of the public health fund in 2000. Rev Méd l’Assurance Maladie 34: 147–156 Kazas E, Grisouard R, Zanni J et al. (2003) Multiple sclerosis treatment with interferon beta: prevalence and cost of the public health fund in 2000. Rev Méd l’Assurance Maladie 34: 147–156
10.
Zurück zum Zitat Kobelt G, Berg J, Atherley D, Hadjimichael O, Jönsson B (2004) Cost and quality of life in multiple sclerosis. A cross-sectional study in the USA. SSE/EFI Working Paper Series in Economics and Finance No. 594. Stockholm School of Economics, Stockholm, Sweden Kobelt G, Berg J, Atherley D, Hadjimichael O, Jönsson B (2004) Cost and quality of life in multiple sclerosis. A cross-sectional study in the USA. SSE/EFI Working Paper Series in Economics and Finance No. 594. Stockholm School of Economics, Stockholm, Sweden
11.
Zurück zum Zitat Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B (2006) Costs and quality of life of multiple sclerosis in Europe. J Neurol (In press) Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B (2006) Costs and quality of life of multiple sclerosis in Europe. J Neurol (In press)
12.
Zurück zum Zitat Miltenburger C, Kobelt G (2002) Quality of life and cost of multiple sclerosis. Clin Neurol Neurosurg 104: 272–275CrossRefPubMed Miltenburger C, Kobelt G (2002) Quality of life and cost of multiple sclerosis. Clin Neurol Neurosurg 104: 272–275CrossRefPubMed
13.
Zurück zum Zitat Jönsson B (1996) Quality of life and health economics. Where is the link? Scand J Gastroenterol Suppl 221: 33–36PubMed Jönsson B (1996) Quality of life and health economics. Where is the link? Scand J Gastroenterol Suppl 221: 33–36PubMed
14.
Zurück zum Zitat Torrance G (1986) Measurement of health state utilities for economic appraisal. A review. J Health Econ 5: 1–30CrossRefPubMed Torrance G (1986) Measurement of health state utilities for economic appraisal. A review. J Health Econ 5: 1–30CrossRefPubMed
15.
Zurück zum Zitat Kobelt G (1996) Health economics: introduction to economic evaluation. Office of Health Economics: London, UK Kobelt G (1996) Health economics: introduction to economic evaluation. Office of Health Economics: London, UK
16.
Zurück zum Zitat Drummond M, O’Brien B, Stoddart G, Torrance G (1997) Methods for the economic evaluation of health care. Kluwer Academic Publishers: Boston, MA, USA Drummond M, O’Brien B, Stoddart G, Torrance G (1997) Methods for the economic evaluation of health care. Kluwer Academic Publishers: Boston, MA, USA
17.
18.
Zurück zum Zitat The EuroQol Group (1990) EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 16: 199–208CrossRefPubMed The EuroQol Group (1990) EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 16: 199–208CrossRefPubMed
19.
Zurück zum Zitat Torrance G (1992) Multi-attribute value and utility functions for a comprehensive health status classification system. McMasters University: Toronto, Ontario, Canada Torrance G (1992) Multi-attribute value and utility functions for a comprehensive health status classification system. McMasters University: Toronto, Ontario, Canada
20.
Zurück zum Zitat Dolan P, Gudex C, Kind P, Williams A (1995) A social tariff for EuroQol: Results from a UK general population survey. Centre for Health Economics, University of York: York, UK Dolan P, Gudex C, Kind P, Williams A (1995) A social tariff for EuroQol: Results from a UK general population survey. Centre for Health Economics, University of York: York, UK
21.
Zurück zum Zitat Henriksson F, Fredrikson S, Jönsson B (2000) Costs, quality of life and disease severity in multiple sclerosis – a cross-sectional study in Sweden. SSE/EFI Working Paper Series in Economics and Finance No. 361. Stockholm School of Economics, Stockholm, Sweden Henriksson F, Fredrikson S, Jönsson B (2000) Costs, quality of life and disease severity in multiple sclerosis – a cross-sectional study in Sweden. SSE/EFI Working Paper Series in Economics and Finance No. 361. Stockholm School of Economics, Stockholm, Sweden
22.
Zurück zum Zitat Kobelt G, Lindgren P, Smala A, Jönsson B, Group Gms (2000) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in Germany. SSE/EFI Working Paper Series in Economics and Finance No. 399. Stockholm School of Economics; Stockholm, Sweden Kobelt G, Lindgren P, Smala A, Jönsson B, Group Gms (2000) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in Germany. SSE/EFI Working Paper Series in Economics and Finance No. 399. Stockholm School of Economics; Stockholm, Sweden
23.
Zurück zum Zitat Eichler H, Kong S, Gerth W, Al E (2004) Use of cost-effectiveness analysis in health care resource allocation decision-making: how are cost-effectivness thresholds expected to emerge? Val Health 7: 518–528CrossRef Eichler H, Kong S, Gerth W, Al E (2004) Use of cost-effectiveness analysis in health care resource allocation decision-making: how are cost-effectivness thresholds expected to emerge? Val Health 7: 518–528CrossRef
24.
Zurück zum Zitat Kurtzke J (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444–1452PubMed Kurtzke J (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444–1452PubMed
25.
Zurück zum Zitat Orlewska E, Mierzejewski P, Zaborski J et al. (2005) A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur J Neurol 12: 31–339CrossRefPubMed Orlewska E, Mierzejewski P, Zaborski J et al. (2005) A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur J Neurol 12: 31–339CrossRefPubMed
26.
Zurück zum Zitat Hohol M, Orav E, Weiner H (1995) Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 45: 251–155PubMed Hohol M, Orav E, Weiner H (1995) Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 45: 251–155PubMed
27.
Zurück zum Zitat Schwartz C, Vollmer T, Lee H (1999) North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Reliability and validity of two self-report measures of impairment and disability for MS. Neurology 52: 63–71PubMed Schwartz C, Vollmer T, Lee H (1999) North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Reliability and validity of two self-report measures of impairment and disability for MS. Neurology 52: 63–71PubMed
28.
Zurück zum Zitat Lublin F, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46: 907–911PubMed Lublin F, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46: 907–911PubMed
29.
Zurück zum Zitat Weinshenker B, Al E (1991) The natural history of multiple sclerosis I and II. Brain 114: 1045–1065PubMed Weinshenker B, Al E (1991) The natural history of multiple sclerosis I and II. Brain 114: 1045–1065PubMed
30.
Zurück zum Zitat Kurtzke J (1955) A new scale for evaluating disability in multiple sclerosis. Neurology 5: 580–583PubMed Kurtzke J (1955) A new scale for evaluating disability in multiple sclerosis. Neurology 5: 580–583PubMed
31.
Zurück zum Zitat Kobelt G, Jönsson L, Fredrikson S (2003) A new disease model to estimate the cost of disease progression for different types of MS and different subgroups of patients. Eur J Health Econ 4: 50–59CrossRefPubMed Kobelt G, Jönsson L, Fredrikson S (2003) A new disease model to estimate the cost of disease progression for different types of MS and different subgroups of patients. Eur J Health Econ 4: 50–59CrossRefPubMed
32.
Zurück zum Zitat Koopmanschap M, Rutten F, Vanineveld B, Vanroijen L (1995) The friction cost method for measuring indirect costs of disease. J Health Econ 14: 171–189 CrossRefPubMed Koopmanschap M, Rutten F, Vanineveld B, Vanroijen L (1995) The friction cost method for measuring indirect costs of disease. J Health Econ 14: 171–189 CrossRefPubMed
Metadaten
Titel
Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis
verfasst von
Gisela Kobelt
Jenny Berg
Peter Lindgren
Bengt Jönsson
Publikationsdatum
01.07.2006
Verlag
Springer-Verlag
Erschienen in
The European Journal of Health Economics / Ausgabe Sonderheft 2/2006
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-006-0365-y

Weitere Artikel der Sonderheft 2/2006

The European Journal of Health Economics 2/2006 Zur Ausgabe

Editorial

Foreword